The short answer
Have goldenseal reviewed before taking it with oral triamcinolone. Human studies show CYP3A inhibition with goldenseal, but they do not establish the effect on triamcinolone itself.
What this answer covers
Oral Hydrastis canadensis preparations with oral plain triamcinolone; not an equivalent claim for isolated berberine or injected/topical products.
- Supplement or preparation
- Hydrastis canadensis
- Medication ingredient
- triamcinolone
Confirm which triamcinolone you use
This advice concerns plain triamcinolone tablets taken by mouth. Creams, nasal products and injections often contain a different triamcinolone form and have different exposure. Ask your pharmacist to check the full ingredient and route before applying this advice.
What human studies found
Goldenseal increased exposure to midazolam, a medicine used to measure CYP3A activity. A later investigation supported an important intestinal component. Neither study tested triamcinolone treatment outcomes.
Check the whole supplement
Bring the botanical name, extract details and full ingredients. Goldenseal findings cannot be assumed to apply in the same way to isolated berberine or every multi-ingredient herbal product.
Do not rely on a dosing gap
No validated interval shows that separating goldenseal from triamcinolone prevents a metabolism interaction. Your pharmacist can assess whether to avoid the supplement; do not adjust the steroid yourself.
Evidence and practical considerations
Absorption & effectiveness
Goldenseal inhibition of oral midazolam disposition and the triamcinolone CYP3A4 label warning justify a cautious review. The exact absorption/effectiveness claim remains unproven.
- Exact scope
- Oral Hydrastis canadensis preparations with oral plain triamcinolone; not an equivalent claim for isolated berberine or injected/topical products. with Plain triamcinolone tablets taken orally, exact RxCUI 10759; other forms and routes require separate product assessment.
- Medication form and route
- oral
- Timing or duration
- Dose and duration matter; bone guidance principally concerns prolonged systemic treatment.
What remains uncertain
- No exact triamcinolone study or quantitative prediction; preparation composition and intestinal versus hepatic mechanisms matter.
Factors that may matter: exact formulation and route; dose and duration; other medicines; supplement preparation; individual nutritional or electrolyte status.
Read the supporting source summaries
Source 1: official product label
swissmedicinfo-pro.ch · Source check Sep 10, 2026
Population: Patients prescribed oral plain triamcinolone.
Risks depend on dose and duration. Lists osteoporosis, muscle weakness, protein catabolism, sodium/fluid retention and potassium loss. Advises protein- and vitamin-rich diet. Specifically names Hypericum perforatum as an inducer that can reduce triamcinolone effect. CYP3A4 inhibitors can reduce clearance. Monitor potassium with potassium-losing medicines and replace if needed.
How this applies: Exact RxCUI 10759 IN identity supported by ingredient name and RxNav record. German professional information translated for scoped oral-product conclusions.
Plain triamcinolone has little mineralocorticoid activity. This is not an acetonide, diacetate or hexacetonide label; topical, inhaled and injected products cannot be assigned the same exposure or precautions automatically. No universal supplement spacing or dose is established.
Source 2: original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Sixteen healthy volunteers.
Goldenseal increased midazolam exposure and inhibited CYP3A activity; kava did not alter midazolam disposition.
How this applies: Exact study exposure only; no transfer of quantitative effects to triamcinolone.
No triamcinolone, no steroid clinical outcomes. Exact extract findings do not establish equivalent effects for all Hydrastis products, berberine alone or nonoral steroid routes.
Source 3: original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy adults plus intestinal microsomes and pharmacokinetic modeling.
Midazolam exposure rose 40-60%; modest or absent half-life change and integrated experiments supported primarily intestinal CYP3A inhibition, with hydrastine an important contributor.
How this applies: Exact study exposure only; no transfer of quantitative effects to triamcinolone.
Not triamcinolone. Mechanistic modeling and surrogate-drug observations cannot quantify this exact pair or establish an injection interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact current claim adjudicated against captured originals with explicit oral-formulation boundary; no clinical review asserted. | |
| Research summary published |
Article revision: 93d4d7c2e5b532ae
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.